|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Sanpower_Group
|
|
gptkbp:acquisitionYear
|
2017
|
|
gptkbp:filedForBankruptcy
|
2014
|
|
gptkbp:focusesOn
|
immunotherapy
|
|
gptkbp:founded
|
1992
|
|
gptkbp:founder
|
gptkb:Christopher_S._Henney
|
|
gptkbp:headquarters_location
|
gptkb:Seal_Beach,_California,_United_States
|
|
gptkbp:headquartersLocation
|
gptkb:Seattle,_Washington,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dendreon Corporation
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableEmployee
|
Paul A. Frohna
|
|
gptkbp:notableProduct
|
gptkb:Provenge
|
|
gptkbp:parentOrganization
|
Nanjing Cenbest
|
|
gptkbp:product_approved_by
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:Provenge_approval_year
|
2010
|
|
gptkbp:Provenge_approved_for
|
prostate cancer
|
|
gptkbp:stockSymbol
|
gptkb:DNDN
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.dendreon.com/
|
|
gptkbp:bfsParent
|
gptkb:Mitchell_H._Gold
|
|
gptkbp:bfsLayer
|
7
|